
    
      Treatment until disease progression or no evidence of treatment response; occurrence of
      unacceptable toxicity, intercurrent medical problem, or adverse event (AE); or a maximum of 6
      cycles.

      Follow-up of 6 months after the last treatment with alvocidib.

      The maximum duration of the study participation for patient will be about 15 months.
    
  